The randomized clinical trial will include 2,000 participants at high risk for an undiagnosed irregular heartbeat. It will compare patients wearing an Apple Watch and outfitted with the Mayo Clinic ECG Study App to people in a control group receiving usual care.
The study is expected to start in September and conclude in 2026. Mayo Clinic researchers previously found the Apple Watch could be used for identifying patients with a weak heart pump.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.